Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.

Nassar AH, Hamieh L, Gray KP, Thorner AR, Fay AP, Lasseter KD, Abou Alaiwi S, Nuzzo PV, Flippot R, Krajewski KM, Signoretti S, Choueiri TK, Kwiatkowski DJ.

Mol Cancer Ther. 2019 Oct 25. pii: molcanther.0642.2019. doi: 10.1158/1535-7163.MCT-19-0642. [Epub ahead of print]

PMID:
31653662
2.

Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery.

de Cássio Zequi S, da Costa WH, Korkes F, Dos Reis RB, Busato WFS, Matheus WE, da Silva Neto DCV, de Almeida E Paula F, Carvalhal GF, Nogueira L, de Carvalho Fernandes R, Silva AGE, Sasse AD, Fay AP, Jardim DL, Bastos DA, da Rosa DAR, Wierman E, Kater F, Schutz FA, Maluf FC, de Oliveira FNG, Morbeck IAP, Rinck JA, da Trindade KM, Maia MC, Souza VC, Monteiro FSM, Soares A.

Ther Adv Urol. 2019 Sep 9;11:1756287219872324. doi: 10.1177/1756287219872324. eCollection 2019 Jan-Dec. Review.

3.

Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?

Fay AP, Antonarakis ES.

Ann Transl Med. 2019 Mar;7(Suppl 1):S7. doi: 10.21037/atm.2019.01.37. No abstract available.

4.

Immunohistochemical analysis of tissue factor expression in gastric carcinoma: correlations with prognosis and survival.

Toneto MG, Depaula PL, Debon L, Tertuliano B, Silva VD, Baldisseroto M, Fay AP, Carvalhal GF.

Rev Col Bras Cir. 2018 Nov 29;45(6):e2030. doi: 10.1590/0100-6991e-20182030. Portuguese, English.

5.
6.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

7.

ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.

Urun Y, Leow JJ, Fay AP, Albiges L, Choueiri TK, Bellmunt J.

Crit Rev Oncol Hematol. 2017 Dec;120:120-126. doi: 10.1016/j.critrevonc.2017.10.012. Epub 2017 Nov 2. Review.

PMID:
29198325
8.

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.

Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA.

Oncotarget. 2017 Aug 8;8(48):84572-84578. doi: 10.18632/oncotarget.20028. eCollection 2017 Oct 13. Review.

9.

Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.

de Velasco G, Gray KP, Hamieh L, Urun Y, Carol HA, Fay AP, Signoretti S, Kwiatkowski DJ, McDermott DF, Freedman M, Pomerantz MM, Choueiri TK.

Eur Urol Focus. 2016 Dec 15;2(6):633-639. doi: 10.1016/j.euf.2016.03.017. Epub 2016 Apr 23.

10.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK.

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

11.

Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma.

Teló GH, Carvalhal GF, Cauduro CGS, Webber VS, Barrios CH, Fay AP.

Ann Oncol. 2017 Jan 1;28(1):191-192. doi: 10.1093/annonc/mdw447. No abstract available.

PMID:
28043983
12.

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DYC, Choueiri TK.

J Clin Oncol. 2016 Oct 20;34(30):3655-3663. doi: 10.1200/JCO.2016.66.7311.

13.

Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK.

J Natl Compr Canc Netw. 2016 Jul;14(7):820-4.

14.

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.

Bellmunt J, Zhou CW, Mullane SA, Werner L, Taplin ME, Fay AP, Choueiri TK, Orsola A, Takeda DY, Hahn WC, Kim J, Sonpavde G, Bowden M.

Br J Cancer. 2016 Jun 28;115(1):12-9. doi: 10.1038/bjc.2016.146. Epub 2016 Jun 23.

15.

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.

Mahoney KM, Jacobus S, Bhatt RS, Song J, Carvo I, Cheng SC, Simpson M, Fay AP, Puzanov I, Michaelson MD, Atkins MB, McDermott DF, Signoretti S, Choueiri TK.

Clin Genitourin Cancer. 2016 Aug;14(4):304-313.e6. doi: 10.1016/j.clgc.2016.02.007. Epub 2016 Feb 23.

PMID:
27036973
16.

Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.

Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, Broom R, Fay AP, Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, Kanesvaran R, Alimohamed N, Hermanns T, Wells JC, Amir E, Choueiri TK, Heng DY.

Eur Urol. 2016 Aug;70(2):358-64. doi: 10.1016/j.eururo.2016.02.033. Epub 2016 Feb 28.

PMID:
26924770
17.

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.

Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen E, Krajewski KM, Porta C, Pal S, Bellmunt J, McDermott DF, Heng DYC, Gray KP, Signoretti S.

Clin Cancer Res. 2016 May 15;22(10):2445-2452. doi: 10.1158/1078-0432.CCR-15-2631. Epub 2016 Feb 1.

18.

Statins and survival outcomes in patients with metastatic renal cell carcinoma.

McKay RR, Lin X, Albiges L, Fay AP, Kaymakcalan MD, Mickey SS, Ghoroghchian PP, Bhatt RS, Kaffenberger SD, Simantov R, Choueiri TK, Heng DY.

Eur J Cancer. 2016 Jan;52:155-62. doi: 10.1016/j.ejca.2015.10.008. Epub 2015 Dec 11.

PMID:
26687834
19.

Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective.

Albiges L, Fay AP, McKay RR, Kaymakcalan MD, Choueiri TK.

Surg Pathol Clin. 2015 Dec;8(4):657-62. doi: 10.1016/j.path.2015.08.001. Review.

PMID:
26612219
20.

Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK.

Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5.

21.

Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer?

Fay AP, Bellmunt J.

BJU Int. 2015 Oct;116(4):500-1. doi: 10.1111/bju.13070. No abstract available.

22.

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.

Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DY, Dariane C, DeVelasco G, Lester R, Escudier B, Choueiri TK.

Eur J Cancer. 2015 Nov;51(17):2580-6. doi: 10.1016/j.ejca.2015.08.017. Epub 2015 Sep 4.

PMID:
26346135
23.

Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.

Bellmunt J, Werner L, Leow JJ, Mullane SA, Fay AP, Riester M, Van Hummelen P, Taplin ME, Choueiri TK, Van Allen E, Rosenberg J.

PLoS One. 2015 Jun 3;10(6):e0124711. doi: 10.1371/journal.pone.0124711. eCollection 2015.

24.

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.

Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S.

Cancer Immunol Res. 2015 Oct;3(10):1158-64. doi: 10.1158/2326-6066.CIR-15-0043. Epub 2015 May 26.

25.

Perioperative therapy for muscle invasive bladder cancer.

Leow JJ, Fay AP, Mullane SA, Bellmunt J.

Hematol Oncol Clin North Am. 2015 Apr;29(2):301-18, ix. doi: 10.1016/j.hoc.2014.11.002. Review.

PMID:
25836936
26.

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.

Fay AP, Signoretti S, Callea M, Telό GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK.

J Immunother Cancer. 2015 Feb 17;3:3. doi: 10.1186/s40425-015-0047-3. eCollection 2015.

27.

HER2 as a target in invasive urothelial carcinoma.

Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J.

Cancer Med. 2015 Jun;4(6):844-52. doi: 10.1002/cam4.432. Epub 2015 Feb 26.

28.

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.

Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, Taplin ME, Choueiri TK, Hodi FS, Freeman GJ, Signoretti S.

Ann Oncol. 2015 Apr;26(4):812-7. doi: 10.1093/annonc/mdv009. Epub 2015 Jan 18.

PMID:
25600565
29.

Current role of cabozantinib in metastatic castration-resistant prostate cancer.

Fay AP, Albiges L, Bellmunt J.

Expert Rev Anticancer Ther. 2015 Feb;15(2):151-6. doi: 10.1586/14737140.2015.1003047. Epub 2015 Jan 14. Review.

PMID:
25586337
30.

Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.

Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C, Benson P, Ho TH, Pandite L, de Souza P, Powles T, Motzer RJ.

Clin Cancer Res. 2015 Mar 1;21(5):1071-7. doi: 10.1158/1078-0432.CCR-14-1993. Epub 2014 Dec 23.

31.

Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium.

Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng DY.

Clin Genitourin Cancer. 2015 Apr;13(2):150-5. doi: 10.1016/j.clgc.2014.09.003. Epub 2014 Oct 2.

PMID:
25458371
32.

PD-L1 expression in nonclear-cell renal cell carcinoma.

Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S.

Ann Oncol. 2014 Nov;25(11):2178-84. doi: 10.1093/annonc/mdu445. Epub 2014 Sep 5.

33.
34.

Identification of ALK gene alterations in urothelial carcinoma.

Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE.

PLoS One. 2014 Aug 1;9(8):e103325. doi: 10.1371/journal.pone.0103325. eCollection 2014.

35.

Adrenocortical carcinoma: the management of metastatic disease.

Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, Bellmunt J, Choueiri TK.

Crit Rev Oncol Hematol. 2014 Nov;92(2):123-32. doi: 10.1016/j.critrevonc.2014.05.009. Epub 2014 Jun 4. Review.

36.

MET as a target in papillary renal cell carcinoma.

Fay AP, Signoretti S, Choueiri TK.

Clin Cancer Res. 2014 Jul 1;20(13):3361-3. doi: 10.1158/1078-0432.CCR-14-0690. Epub 2014 May 8.

37.

Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.

Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK.

Clin Genitourin Cancer. 2014 Aug;12(4):262-9. doi: 10.1016/j.clgc.2014.03.002. Epub 2014 Mar 14.

PMID:
24795159
38.

10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.

Krajewski KM, Franchetti Y, Nishino M, Fay AP, Ramaiya N, Van den Abbeele AD, Choueiri TK.

Oncologist. 2014 May;19(5):507-14. doi: 10.1634/theoncologist.2013-0391. Epub 2014 Apr 22.

39.

A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.

Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J.

Eur Urol. 2014 Sep;66(3):529-41. doi: 10.1016/j.eururo.2014.03.003. Epub 2014 Mar 16. Review.

PMID:
24680361
40.

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S.

Clin Cancer Res. 2013 Sep 15;19(18):5218-26. doi: 10.1158/1078-0432.CCR-13-0491. Epub 2013 Jul 23.

41.

BRAF mutations in metanephric adenoma of the kidney.

Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, McKenney JK, Brown V, Lampron ME, Zhou M, Hirsch MS, Signoretti S.

Eur Urol. 2012 Nov;62(5):917-22. doi: 10.1016/j.eururo.2012.05.051. Epub 2012 Jun 9.

42.

Fresh eyes for chronic care management.

Fay AP.

J Prim Health Care. 2009 Sep;1(3):241-3. No abstract available.

PMID:
20690391

Supplemental Content

Support Center